The VITALITY-HFpEF trial (Evaluate the Efficacy and Safety of the Oral sGC Stimulator Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With Heart Failure and Preserved Ejection Fraction) is designed to determine the efficacy and safety of a novel oral soluble guanylate cyclase stimulator, vericiguat, on quality of life and exercise tolerance in heart failure patients with preserved ejection fraction (HFpEF)


The VITALITY-HFpEF study was presented on June 12, 2020 during HFA Discoveries, an online initiative from the European Society of Cardiology Heart Failure Association.

Please note a My ESC account is required to view the on-demand webinar presentation for VITALITY-HFpEF


Javed Butler, Carolyn S P Lam, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Christopher M O’Connor, Burkert Pieske, Piotr Ponikowski, Sanjiv J Shah, Scott D Solomon, Adriaan A Voors, Yi Wu, Francine Carvalho, Luke Bamber, Robert O Blaustein, Lothar Roessig, Paul W Armstrong. Rationale and Design of the VITALITY-HFpEF Trial. Circ Heart Fail. 2019 May;12:e005998. doi: 10.1161/CIRCHEARTFAILRE.119.005998.

Media Coverage

New Vericiguat Shine May Not Brighten Heart Failure With Preserved LVEF (Medscape)

Data Sharing

Trial data will be made accessible after completion of the studies’ analytical phases.